∙ Stage 1:

• Age 18-years-old or older

• Identifies as Black or African American, by either chart documentation or participant self-report. Mixed-race including Black or African American is included.

• Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.

• Able to understand study procedures and to comply with them for the entire length of the study.

• Able to understand a written information sheet and willing to verbally consent.

• Fluent in English (reading, writing, and speaking)

∙ Stage 2:

• Age 18-years-old or older

• Identifies as Black or African-American, by either chart documentation or participant self-report. Mixed-race including Black or African-American is included.

• Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.

• Able to understand study procedures and to comply with them for the entire length of the study.

• Fluent in English (reading, writing, and speaking).

• Anticipated discussion of TGT within 0-90 days of enrollment, per treating oncology provider's discretion. TGT involves use of any cancer genetic sequencing (whether standard-of-care or part of a research protocol) via any one of the following:

‣ Somatic DNA testing of already-collected tissue.

⁃ Somatic DNA testing of tissue to be collected in the future via biopsy, surgery, or other procedure.

⁃ Blood-based DNA testing to evaluate for circulating tumor DNA.

• Able to understand a written informed consent document and willing to sign it.